Pharmacological chaperoning: A potential treatment for PMM2‐CDG
P Yuste‐Checa, S Brasil, A Gámez… - Human …, 2017 - Wiley Online Library
The congenital disorder of glycosylation (CDG) due to phosphomannomutase 2 deficiency
(PMM2‐CDG), the most common N‐glycosylation disorder, is a multisystem disease for …
(PMM2‐CDG), the most common N‐glycosylation disorder, is a multisystem disease for …
Pharmacological Chaperoning: A Potential Treatment for PMM2‐CDG
P Yuste‐Checa, S Brasil, A Gámez, J Underhaug… - Human Mutation, 2017 - infona.pl
The congenital disorder of glycosylation (CDG) due to phosphomannomutase 2 deficiency
(PMM2‐CDG), the most common N‐glycosylation disorder, is a multisystem disease for …
(PMM2‐CDG), the most common N‐glycosylation disorder, is a multisystem disease for …
Pharmacological Chaperoning: A Potential Treatment for PMM2-CDG
P Yuste-Checa, S Brasil, A Gámez… - Human …, 2017 - pubmed.ncbi.nlm.nih.gov
The congenital disorder of glycosylation (CDG) due to phosphomannomutase 2 deficiency
(PMM2-CDG), the most common N-glycosylation disorder, is a multisystem disease for …
(PMM2-CDG), the most common N-glycosylation disorder, is a multisystem disease for …
Pharmacological Chaperoning: A Potential Treatment for PMM2-CDG.
P Yuste-Checa, S Brasil, A Gámez, J Underhaug… - Human …, 2016 - europepmc.org
The congenital disorder of glycosylation (CDG) due to phosphomannomutase 2 deficiency
(PMM2-CDG), the most common N-glycosylation disorder, is a multisystem disease for …
(PMM2-CDG), the most common N-glycosylation disorder, is a multisystem disease for …